|
1
|
American Cancer Society: Global Cancer
Facts & Figures. 4th edition. American Cancer Society.
(Atlanta, GA). 2018.
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Inamura K: Clinicopathological
characteristics and mutations driving development of early lung
adenocarcinoma: Tumor initiation and progression. Int J Mol Sci.
19:12592018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung Cancer/American thoracic Society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoshida Y, Nitadori JI, Shinozaki-Ushiku
A, Sato J, Miyaji T, Yamaguchi T, Fukayama M and Nakajima J:
Micropapillary histological subtype in lung adenocarcinoma of 2 cm
or less: Impact on recurrence and clinical predictors. Gen Thorac
Cardiovasc Surg. 65:273–279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miyoshi T, Satoh Y, Okumura S, Nakagawa K,
Shirakusa T, Tsuchiya E and Ishikawa Y: Early-stage lung
adenocarcinomas with a micropapillary pattern, a distinct
pathologic marker for a significantly poor prognosis. Am J Surg
Pathol. 27:101–109. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
World Health Organization: WHO
Classification of Tumors of the Lung, Pleura, Thymus and Heart.
Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: WHO/IARC
Classification of Tumours. Lyon. (IARC Publications). 2015.
|
|
8
|
Matsuo Y, Shiomi K, Sonoda D, Mikubo M,
Naito M, Matsui Y, Yoshida T and Satoh Y: Molecular alterations in
a new cell line (KU-Lu-MPPt3) established from a human lung
adenocarcinoma with a micropapillary pattern. J Cancer Res Clin
Oncol. 144:75–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo X, Zheng E, Wei L, Zeng H, Qin H,
Zhang X, Liao M, Chen L, Zhao L, Ruan XZ, et al: The fatty acid
receptor CD36 promotes HCC progression through activating
Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis.
12:3282021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bellezza G, Vannucci J, Bianconi F, Metro
G, Del Sordo R, Andolfi M, Ferri I, Siccu P, Ludovini V, Puma F, et
al: Prognostic implication of aquaporin 1 overexpression in
resected lung adenocarcinoma. Interact Cardiovasc Thorac Surg.
25:856–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cifarelli V, Appak-Baskoy S, Peche VS,
Kluzak A, Shew T, Narendran R, Pietka KM, Cella M, Walls CW,
Czepielewski R, et al: Visceral obesity and insulin resistance
associate with CD36 deletion in lymphatic endothelial cells. Nat
Commun. 12:33502021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gan G, Shi Z, Shangguan C, Zhang J, Yuan
Y, Chen L, Liu W, Li B, Meng S, Xiong W and Mi J: The kynurenine
derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib
by upregulating phosphatases. Theranostics. 11:6006–6018. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elsayed AM, Bayraktar E, Amero P, Salama
SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK,
Lopez-Berestein G, et al: PRKAR1B-AS2 long noncoding rna promotes
tumorigenesis, survival, and chemoresistance via the PI3K/AKT/mTOR
pathway. Int J Mol Sci. 22:18822021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Hou W, Perera A, Bettler C, Beach
JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, et al:
Targeting EphA2 suppresses hepatocellular carcinoma initiation and
progression by dual inhibition of JAK1/STAT3 and AKT signaling.
Cell Rep. 34:1087652021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Subotički T, Mitrović Ajtić O,
Beleslin-Čokić BB, Bjelica S, Djikić D, Diklić M, Leković D, Gotić
M, Santibanez JF, Noguchi CT and Čokić VP: IL-6 stimulation of DNA
replication is JAK1/2 mediated in cross-talk with hyperactivated
ERK1/2 signaling. Cell Biol Int. 43:192–206. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deramaudt TB, Dujardin D, Noulet F, Martin
S, Vauchelles R, Takeda K and Rondé P: Altering FAK-paxillin
interactions reduces adhesion, migration and invasion processes.
PLoS One. 9:e920592014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song M, Hu J and Quan HY: Abnormal
expression of FAK and paxillin correlates with oral cancer invasion
and metastasis. Acta Biochim Pol. 68:317–323. 2021.PubMed/NCBI
|
|
19
|
Tang J, Kang Y, Huang L, Wu L and Peng Y:
TIMP1 preserves the blood-brain barrier through interacting with
CD63/integrin β 1 complex and regulating downstream FAK/RhoA
signaling. Acta Pharm Sin B. 10:987–1003. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song G, Xu S, Zhang H, Wang Y, Xiao C,
Jiang T, Wu L, Zhang T, Sun X, Zhong L, et al: TIMP1 is a
prognostic marker for the progression and metastasis of colon
cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer
Res. 35:1482016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song Z, Zhu H, Guo Z, Wu W, Sun W and
Zhang Y: Prognostic value of the IASLC/ATS/ERS classification in
stage I lung adenocarcinoma patients-based on a hospital study in
China. Eur J Surg Oncol. 39:1262–1268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshizawa A, Motoi N, Riely GJ, Sima CS,
Gerald WL, Kris MG, Park BJ, Rusch VW and Travis WD: Impact of
proposed IASLC/ATS/ERS classification of lung adenocarcinoma:
Prognostic subgroups and implications for further revision of
staging based on analysis of 514 stage I cases. Mod Pathol.
24:653–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nitadori JI, Bograd AJ, Kadota K, Sima CS,
Rizk NP, Morales EA, Rusch VW, Travis WD and Adusumilli PS: Impact
of micropapillary histologic subtype in selecting limited resection
vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl
Cancer Inst. 105:1212–1220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsubokawa N, Mimae T, Sasada S, Yoshiya T,
Mimura T, Murakami S, Ito H, Miyata Y, Nakayama H and Okada M:
Negative prognostic influence of micropapillary pattern in stage IA
lung adenocarcinoma. Eur J Cardiothorac Surg. 49:293–299. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamiya K, Hayashi Y, Douguchi J,
Hashiguchi A, Yamada T, Izumi Y, Watanabe M, Kawamura M, Horinouchi
H, Shimada N, et al: Histopathological features and prognostic
significance of the micropapillary pattern in lung adenocarcinoma.
Mod Pathol. 21:992–1001. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Watanabe M, Yokose T, Tetsukan W, Imai K,
Tsuboi M, Ito H, Ishikawa Y, Yamada K, Nakayama H and Fujino S:
Micropapillary components in a lung adenocarcinoma predict stump
recurrence 8 years after resection: A case report. Lung Cancer.
80:230–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morimoto J, Nakajima T, Suzuki H, Nagato
K, Iwata T, Yoshida S, Fukuyo M, Ota S, Nakatani Y and Yoshino I:
Impact of free tumor clusters on prognosis after resection of
pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 152:64–72.e1.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Erhart F, Blauensteiner B, Zirkovits G,
Printz D, Soukup K, Klingenbrunner S, Fischhuber K, Reitermaier R,
Halfmann A, Lötsch D, et al: Gliomasphere marker combinatorics:
Multidimensional flow cytometry detects
CD44+/CD133+/ITGA6+/CD36+
signature. J Cell Mol Med. 23:281–292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ghoneum A, Gonzalez D, Abdulfattah AY and
Said N: Metabolic plasticity in ovarian cancer stem cells. Cancers
(Basel). 12:12672020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff
R, Xiong X and Sun Y: The FBXW2-MSX2-SOX2 axis regulates stem cell
property and drug resistance of cancer cells. Proc Natl Acad Sci
USA. 116:20528–20538. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boumahdi S, Driessens G, Lapouge G, Rorive
S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E,
et al: SOX2 controls tumour initiation and cancer stem-cell
functions in squamous-cell carcinoma. Nature. 511:246–250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maréchal R, Demetter P, Nagy N, Berton A,
Decaestecker C, Polus M, Closset J, Devière J, Salmon I and Van
Laethem JL: High expression of CXCR4 may predict poor survival in
resected pancreatic adenocarcinoma. Br J Cancer. 100:1444–1451.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo Y, Dallaglio K, Chen Y, Robinson WA,
Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris
DA, et al: ALDH1A isozymes are markers of human melanoma stem cells
and potential therapeutic targets. Stem Cells. 30:2100–2113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chefetz I, Grimley E, Yang K, Hong L,
Vinogradova EV, Suciu R, Kovalenko I, Karnak D, Morgan CA,
Chtcherbinine M, et al: A Pan-ALDH1A inhibitor induces necroptosis
in ovarian cancer stem-like cells. Cell Rep. 26:3061–3075.e6. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SB, Dent R, Im SA, Espié M, Blau S,
Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, et al:
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as
first-line therapy for metastatic triple-negative breast cancer
(LOTUS): A multicentre, randomised, double-blind,
placebo-controlled, phase 2 trial. Lancet Oncol. 18:1360–1372.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Martorana F, Motta G, Pavone G, Motta L,
Stella S, Vitale SR, Manzella L and Vigneri P: AKT inhibitors: New
weapons in the fight against breast cancer? Front Pharmacol.
12:6622322012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Soria JC, Gan HK, Blagden SP, Plummer R,
Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque
A, et al: A phase I, pharmacokinetic and pharmacodynamic study of
GSK2256098, a focal adhesion kinase inhibitor, in patients with
advanced solid tumors. Ann Oncol. 27:2268–2274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mohanty A, Pharaon RR, Nam A, Salgia S,
Kulkarni P and Massarelli E: FAK-targeted and combination therapies
for the treatment of cancer: An overview of phase I and II clinical
trials. Expert Opin Investig Drugs. 29:399–409. 2020. View Article : Google Scholar : PubMed/NCBI
|
